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Objective: Term pregnancy with choriocarcinoma is a rare condition that can be a serious health threat to
both the mother and the fetus. We present a rare case of term pregnancy with choriocarcinoma pre-
senting as severe fetal anemia and postpartum hemorrhage.
Case Report: A 34-year-old woman, gravida 3 para 2, was admitted for profuse vaginal bleeding 2 weeks
after cesarean delivery of a full-term anemic baby. Transvaginal sonography revealed a 4.7-cm  10.6-cm
heterogenous lesion in the endometrial cavity. Dilatation and curettage was done and a pathologic report
revealed choriocarcinoma. Metastatic workup showed lung metastasis. The patient achieved remission
after eight cycles of chemotherapy in the form of etoposide, methotrexate, actinomycin D, cyclophos-
phamide, and vincristine. There was no evidence of recurrence in the subsequent 3 years of regular
follow up.
Conclusion: Although fetomaternal hemorrhage is a rare form of presentation of choriocarcinoma, its
presence should alert the physician to investigate the cause further. This chemotherapy regimen was
effective in our case and the patient needed to be followed up carefully.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Term pregnancy with choriocarcinoma is a rare condition
[1e10] that may present as hydrops fetalis [11], intrauterine fetal
death, fetomaternal hemorrhage (FMH), and postpartum hemor-
rhage [2]. Postpartum treatment with multiagent chemotherapy is
successful in most cases of choriocarcinoma [12,13], and timely
diagnosis is prognostically important, both for the mother and
the infant.and Gynecology, Chang Gung
g Gung University College of
aiwan.
uang).
bstetrics & Gynecology. PublishedCase Report
A 34-year-old woman (gravida 3 para 2) presented to our hos-
pital with a chief complaint of decreased fetal movements in the
37th week of gestation. Ultrasonography showed a normal fetus
with oligohydramnios (amniotic ﬂuid index ¼ 4.1 cm). Fetal moni-
toring revealed a sinusoidal heart rate pattern (Figure 1). Per
vaginal examination showed cervical dilation of 0.5 cm. A male
infant (2650 g) was delivered by emergency cesarean with Apgar
scores of 2 and 3 at 1 minute and 5 minutes, respectively. The
neonatewas palewithmarked anemia (hemoglobin level ¼ 3.7 g/L)
and was admitted to the intensive care unit for intubation and
blood transfusion. The mother was subsequently discharged 4 days
after the cesarean delivery, but returned 2 weeks postpartum
because of profuse vaginal bleeding. Transvaginal ultrasonographyby Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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(Figure 2A) with increased vascularity (Figure 2B). Dilatation and
curettage was performed and pathological analysis revealed
choriocarcinoma. Metastatic workup was performed. Computed
tomography revealed a heterogenous mass measuring
16 cm  12 cm  9 cm in the uterine cavity (Figures 3A and 3B) and
multiple lung metastases (Figure 3C). The level of serum b human
chorionic gonadotropin was 538,312 mIU/mL. The patient was
classiﬁed as Stage III in the International Federation of Gynecology
and Obstetrics anatomic scoring system and had a score of 13 in the
World Health Organization prognostic scoring system. She ach-
ieved complete remission (CR) after eight cycles of chemotherapy
in the form of etoposide, methotrexate, actinomycin D, cyclo-
phosphamide, and vincristine (EMA-CO). There was no evidence of
recurrence in the subsequent 3 years of regular follow up.Figure 2. Ultrasonography at 2 weeks postpartum showing (A) a heterogenous lesion
4.7 cm  10.6 cm (indicated by arrowhead) in the uterine cavity with (B) increased
vascularity.Discussion
Term pregnancy with choriocarcinoma is a rare condition
[1e10]. The diagnosis is usually conﬁrmed by the histopathological
examination of the placenta after delivery or from samples of
dilatation and curettage for postpartum hemorrhage. These cases
may present as hydrops fetalis [11], intrauterine fetal death, FMH,
and postpartum hemorrhage [2]. The last two symptoms were
evident in the present case.
Previous studies have shown that choriocarcinoma is often
incidentally discovered on histopathological examination. In a
report of ﬁve cases of term pregnancies with choriocarcinoma [1],
placentas of three of the cases were grossly similar with a single
small lesion suggesting a small infarct. These lesions were
conﬁrmed to be choriocarcinoma on microscopic examination. The
placenta of the fourth case contained a large marginal lesion
microscopically identiﬁed as choriocarcinoma. The placenta of the
ﬁfth case had rare microscopic foci of choriocarcinoma and sheets
of necrotic choriocarcinoma were identiﬁed in a blood clot sub-
mitted for analysis with the placenta. In another report of four cases
of 3rd-trimester pregnancy with choriocarcinoma [8], the placentas
in all cases were unremarkable macroscopically with small
nondescript lesions, which were considered to be fresh infarcts or
intervillus thrombi. These ﬁndings suggest that choriocarcinoma
lesions in term pregnancy are easily overlooked by the gross ex-
amination of the placenta [1,4,7,8]. Therefore, it is highly recom-
mended to submit the placenta for microscopic examination in
suspicious cases.
Maternal and fetal complications in pregnancy are increased by
choriocarcinoma and include vaginal bleeding, hydrops fetalis [11],
FMH [10,11,14,15], intrauterine fetal death [6], and postpartum
hemorrhage [12,13]. FMH can lead to preterm labor [16], decreasedFigure 1. Sinusoidal patteor absent fetal movements [11,16,17], fetal distress with a sinusoidal
heart rate pattern, and neonatal death [17e19]. The most common
presenting symptoms of FMH are anemia at birth (35.2%),
decreased or absent fetal movements (26.8%), and unexpected
stillbirth (12.5%) [16]. Prenatal ﬁndings of decreased or absent fetal
body movements, sinusoidal heart rate pattern, or hydrops fetalis
are usually late signs of FMH [16], making early detection relatively
difﬁcult.
The prognosis of patients diagnosed with choriocarcinoma is
good, if an appropriate chemotherapeutic regimen is started early.
A retrospective study reported CR in 87.8% of patients following thern of fetal heartbeat.
Figure 3. Computed tomography revealed (A, B) a heterogenous mass lesion measuring 16 cm  12 cm  9 cm in the uterine cavity and (C) multiple small nodules in lung ﬁelds.
H.-H. Peng et al. / Taiwanese Journal of Obstetrics & Gynecology 55 (2016) 430e433432administration of an average of 8.5 cycles of chemotherapy com-
bined with comprehensive therapy [20]. The CR rates for patients
diagnosed as FIGO (International Federation of Gynecology and
Obstetrics) Stage I, II, III, and IV were 100%, 100%, 91%, and 62.5%,
respectively. A shortened time interval between the antecedent
pregnancy and treatment was correlated with improved prognosis.
EMA-CO is the most commonly used combination chemotherapy to
treat high-risk gestational trophoblastic neoplasia because it has
the best efﬁcacy-to-toxicity ratio. In a series of 272 women with
high-risk gestational trophoblastic neoplasia who were treated
with EMA-CO, 78% achieved CR [21]. A 16-year retrospective study
of post-term choriocarcinoma patients at the New England
Trophoblastic Diseases Center (Boston, USA) reported a survival
rate of 87.5% [22].
In cases refractory to EMA-CO or relapse from EMA-CO
chemotherapy, researchers reported that EMA-EP (etoposide and
cisplatin) is an effective but moderately toxic regimen [23,24].
In summary, pregnancy with choriocarcinoma can be a serious
health threat to both the mother and the fetus. Early diagnosis
depends on a combination of detecting an unusually high level of
serum b human chorionic gonadotropin, hydrops fetalis, fetal
anemia, and postpartum hemorrhage. Although FMH is a rare form
of presentation of choriocarcinoma, its presence should alert the
physician to investigate the cause further. Chemotherapy with
EMA-CO is effective in most cases. However, patients must be fol-
lowed up carefully and any recurrent disease should be aggres-
sively managed.Conﬂicts of interest
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